Will marijuana be rescheduled?
Short Answer
Both the model and the market overwhelmingly agree that marijuana will be rescheduled before Jan 20, 2029, with only minor residual uncertainty.
1. Executive Verdict
- Trump administration took concrete steps towards broader marijuana rescheduling.
- An administrative hearing to evaluate rescheduling is scheduled for mid-2026.
- Finalization of broader rescheduling by July 15, 2026, is extremely unlikely.
- Finalization by year-end 2026 appears highly improbable, given typical timelines.
- Internal opposition and litigation may significantly delay the rescheduling process.
- The Department of Justice finalized a partial rescheduling rule in April 2026.
Who Wins and Why
| Outcome | Market | Model | Why |
|---|---|---|---|
| Before July 2026 | 0.9% | 0.7% | Finalizing rescheduling before July 2026 is extremely low due to necessary subsequent procedural steps. |
| Before 2027 | 27.0% | 20.8% | Finalizing rescheduling before 2027 is highly improbable due to the July 2026 hearing and typical 18-36 month process. |
| Before 2028 | 70.0% | 72.2% | The Trump administration has taken concrete steps, including an executive order, to expedite rescheduling. |
| Before Jan 20, 2029 | 81.0% | 82.4% | The Trump administration has taken concrete steps, including an executive order, to expedite rescheduling. |
Current Context
The administration recently reclassified certain marijuana products to Schedule III. As of April 23, 2026, the Trump administration officially reclassified FDA-approved marijuana products and state-licensed medical marijuana from Schedule I to Schedule III under the Controlled Substances Act [^][^][^][^]. This action altered the federal classification for specific cannabis-related items.
Broader marijuana rescheduling is progressing, driven by an executive order. The larger initiative to reschedule all marijuana from Schedule I to Schedule III remains an ongoing process, with the Drug Enforcement Administration (DEA) scheduling an administrative hearing to commence on June 29, 2026, to evaluate this proposed change [^][^][^][^]. This expedited rulemaking process for rescheduling marijuana to Schedule III was directed by President Trump's Executive Order 14370, issued on December 18, 2025, which mandated the Attorney General to complete the process as expeditiously as possible [^][^][^][^].
2. Market Behavior & Price Dynamics
Historical Price (Probability)
Outcome probability
Date
This prediction market has exhibited a sideways trend with a slight downward drift, trading within an extremely narrow range of 0.9% to 1.4%. The price started at 1.4% and has since settled near its all-time low of 0.9%, which is acting as a key support level, while 1.4% serves as resistance. Despite a total volume of over 24,000 contracts, the sample data points suggest trading may be infrequent, indicating a general lack of new information or conviction to move the price significantly. The market's stability at this very low probability suggests a strong consensus among traders.
The price action indicates that the market does not view the recent administration action as sufficient to resolve this market as "YES". Even after the administration officially reclassified certain FDA-approved and state-licensed medical marijuana products to Schedule III, the market price remained near its lows. This lack of a positive price response suggests traders interpret the market's resolution criteria as requiring a broader, more comprehensive rescheduling of all marijuana, not just specific products. The persistent low probability implies that traders believe such a comprehensive change is highly unlikely.
Overall, the chart reflects a deeply pessimistic market sentiment regarding the prospect of a full marijuana rescheduling. The price has been static and unresponsive to recent news that might otherwise seem positive. This suggests traders have priced in the partial reclassification as a non-event for the purposes of this specific market and see no catalysts on the horizon that would lead to a "YES" resolution. The low price and sideways movement indicate a stable belief that the conditions for this market will not be met.
3. Market Data
Contract Snapshot
The market resolves to "Yes" if marijuana is legally rescheduled from Schedule I to a lower drug schedule or entirely unscheduled under the Controlled Substances Act before January 1, 2028. It resolves to "No" if this condition is not met by the deadline, and only reclassifying specific cannabis derivatives or cannabinoids without affecting marijuana as a whole does not qualify. For a "Yes" resolution, the rescheduling must have taken legal effect, not merely been announced or published in the Federal Register.
Available Contracts
Market options and current pricing
| Outcome bucket | Yes (price) | No (price) | Last trade probability |
|---|---|---|---|
| Before July 2026 | $0.01 | $0.99 | 1% |
| Before 2027 | $0.29 | $0.73 | 27% |
| Before 2028 | $0.69 | $0.33 | 70% |
| Before Jan 20, 2029 | $0.80 | $0.24 | 81% |
Market Discussion
The market indicates a strong probability (81%) of marijuana being rescheduled by January 2029, though the likelihood drops to 27% for rescheduling by 2027. A key point of discussion and confusion among traders revolves around the specific definition of "rescheduled" under the market rules; some incorrectly believe it has already occurred, prompting clarifications that the entire substance, not just derivatives or medical cannabis, must be removed from Schedule I. Arguments for "Yes" are often rooted in political considerations or perceived government loosening of restrictions, while "No" arguments focus on strict interpretation of the rules and potential legal challenges to rescheduling efforts.
4. What are the key arguments and procedural hurdles anticipated in the DEA's administrative hearing starting June 29, 2026?
| Hearing Start Date | June 29, 2026 [^][^][^][^][^][^] |
|---|---|
| Hearing End Date | July 15, 2026 [^][^][^][^][^][^] |
| Executive Order Date | December 2025 [^][^] |
The DEA’s administrative hearing on marijuana rescheduling begins June 29, 2026. This hearing, scheduled to conclude by July 15, 2026, aims to address crucial arguments regarding data focus for rescheduling and navigate procedural challenges concerning participant selection and legal compliance [^][^][^][^][^][^]. The proceeding was initiated following President Trump's Executive Order 14370 in December 2025, which directed the Attorney General to expedite the rescheduling rulemaking process. This directive led the DEA to terminate previous stalled hearing proceedings [^][^].
Central arguments debate data scope and procedural fairness challenges. A key debate involves whether to concentrate solely on medical and pharmacological data or to also consider the practical, commercial realities of the current state-legal marijuana industry [^][^]. Advocates for reform generally push for descheduling rather than merely rescheduling marijuana to Schedule III, while prohibitionist groups remain opposed to any form of rescheduling [^][^]. Procedural hurdles anticipated include the selection of hearing participants and mitigating potential litigation concerning bias or conflicts of interest. The DEA is also tasked with balancing administrative efficiency with full adherence to the Administrative Procedure Act and the Controlled Substances Act [^][^][^].
5. What evidence points to significant opposition from within the DEA or other federal agencies that could delay rescheduling past July 2026?
| Administrative Hearing Start | June 29, 2026 [^][^][^] |
|---|---|
| Administrative Hearing End | July 24, 2026 [^][^][^] |
| Final Broader Rescheduling Expected | Past July 2026 [^][^] |
Internal DEA opposition and a lengthy hearing timeline impede rescheduling efforts. The rescheduling process faces significant internal opposition and procedural friction within the DEA, including allegations of improper communications with anti-rescheduling parties and stalled administrative appeals [^][^][^]. A critical administrative hearing for the proposed rescheduling is scheduled to begin on June 29, 2026, and conclude by July 24, 2026 [^][^][^]. Given the extensive requirements for this hearing, such as evidence submission, cross-examination, and a subsequent briefing period, the finalization of rescheduling before July 2026 appears highly improbable [^][^].
External legal and legislative actions may further delay rescheduling past 2026. Beyond the DEA's internal challenges and the administrative hearing's schedule, external factors are expected to extend broader rescheduling beyond July 2026 [^][^]. These factors include potential federal litigation, specifically a motion to stay an April 2026 order related to certain marijuana products, and possible Congressional action under the Congressional Review Act [^][^]. Furthermore, prediction markets indicate widespread skepticism regarding a prompt rescheduling outcome [^].
6. How do the legal and economic consequences of the April 2026 partial rescheduling differ from those of a full move to Schedule III for all marijuana?
| Rescheduling effective date | April 23, 2026 [^][^][^] |
|---|---|
| Products affected by rescheduling | FDA-approved and state medical marijuana products [^][^][^] |
| Tax relief for medical operators | Potential elimination of IRC Section 280E disallowance [^][^][^] |
Partial rescheduling offers tax relief for medical marijuana, not adult-use. The April 2026 partial rescheduling, effective April 23, 2026, reclassifies only FDA-approved marijuana products and those regulated by state medical marijuana licenses to Schedule III, leaving adult-use marijuana in Schedule I [^][^][^]. The primary economic consequence is the potential elimination of Internal Revenue Code Section 280E's tax disallowance for compliant medical marijuana operators. This change enables these businesses to deduct ordinary and necessary business expenses, a benefit not extended to adult-use marijuana operators [^][^][^].
Legal complexities arise, impacting dual-licensed operators and future rescheduling. This partial rescheduling introduces new legal challenges, particularly for dual-licensed operators who must segment their revenue between medical and adult-use operations to qualify for 280E relief [^][^][^]. Adult-use activities continue to be subject to full Schedule I criminal and regulatory prohibitions [^][^][^]. Following the announcement, prediction markets indicated a sharp decrease in the short-term probability of full plant rescheduling. This is because the move established an extended administrative hearing process for broader rescheduling, which is set to begin on June 29, 2026 [^][^].
7. What further actions could the Trump administration or the Attorney General take before July 2026 to accelerate the final rescheduling rule?
| Roster Finalization Due | June 22, 2026 [^] |
|---|---|
| DEA Hearing Start | June 29, 2026 [^][^][^][^] |
| Interim Rescheduling Order | April 28, 2026 [^][^][^] |
Finalizing the hearing roster is the critical immediate action needed for rescheduling. The most pressing remaining action to accelerate the final rescheduling rule for marijuana before July 2026 is the Acting Attorney General's finalization of the hearing participant roster. This crucial step, expected by June 22, 2026, will define the scope and potential challenges of the upcoming hearing process [^].
The administration has already taken steps to advance marijuana rescheduling. The Trump administration has significantly expedited the rescheduling process through Executive Order 14370, issued on December 18, 2025. These actions included terminating a prior stalled hearing process and issuing an order on April 28, 2026, which immediately reclassified FDA-approved marijuana products and state-licensed medical marijuana into Schedule III [^][^][^]. However, the legal framework mandates the completion of a full administrative hearing before a final rule for broader rescheduling can be formally enacted [^]. A new administrative hearing concerning the proposed rescheduling of marijuana is scheduled to commence by the DEA on June 29, 2026, with proceedings expected to conclude no later than July 15, 2026 [^][^][^][^].
Beyond roster finalization, few further actions can accelerate the rule. While the Attorney General possesses broad authority under 21 U.S.C. 811 to direct the scheduling process [^], the available information does not specify further actions that could be taken by the administration or Attorney General before July 2026 to accelerate the final rescheduling rule beyond finalizing the hearing participant roster [^].
8. Based on historical precedents, what is the typical timeframe for the DEA to finalize a rescheduling rule after an administrative hearing begins?
| Formal Hearing Start Date | June 29, 2026 [^][^][^] |
|---|---|
| Formal Hearing End Date | No later than July 15, 2026 [^][^][^] |
| Historical Post-Hearing Timeline | 18-36 months (DEA administrative hearing to final rule) [^][^][^] |
A formal hearing on marijuana rescheduling is scheduled for mid-2026. The administrative hearing for the proposed rescheduling of marijuana is set to commence on June 29, 2026, and conclude by July 15, 2026 [^][^][^]. This process is mandated by President Trump's Executive Order 14370, issued on December 18, 2025, which requires the Attorney General to complete the rescheduling [^][^][^].
Historically, DEA rule finalization takes 18 to 36 months. The timeframe from a DEA administrative hearing to the issuance of a final rule has typically been unpredictable, often ranging from 18 to 36 months [^][^][^]. Delays are frequently observed after the conclusion of the hearing, particularly during the Administrator's review of the Administrative Law Judge's recommended decision [^][^][^].
9. What Could Change the Odds
Key Catalysts
The Department of Justice finalized a rule as of April 23, 2026, placing FDA-approved products containing marijuana and products regulated by a state-issued medical marijuana license into Schedule III [^] [^] . Following President Trump's December 18, 2025, Executive Order (E.O. 14370), the DEA initiated a new expedited administrative hearing process regarding the rescheduling of marijuana from Schedule I to Schedule III, scheduled to commence on June 29, 2026, and conclude no later than July 15, 2026 [^][^][^][^].
Prediction markets currently show high sentiment (around 77-83%) that full marijuana rescheduling to Schedule III will occur before January 20, 2029 [^] [^] [^] . | Politics Prediction Markets | Solflare">[^][^][^]. However, near-term confidence (before July 2026) is low (approximately 10-22%) due to the anticipated length of the administrative process [^][^][^]. Market catalysts include the potential elimination of the punitive 280E tax provision, improved institutional capital access, and federal regulatory harmonization, which analysts expect will drive a major industry re-rating upon formal implementation of Schedule III status [^][^][^][^][^].
Key Dates & Catalysts
- Expiration: July 08, 2026
- Closes: January 20, 2029
10. Decision-Flipping Events
- Trigger: The Department of Justice finalized a rule as of April 23, 2026, placing FDA-approved products containing marijuana and products regulated by a state-issued medical marijuana license into Schedule III [^] [^] .
- Trigger: Following President Trump's December 18, 2025, Executive Order (E.O.
- Trigger: 14370), the DEA initiated a new expedited administrative hearing process regarding the rescheduling of marijuana from Schedule I to Schedule III, scheduled to commence on June 29, 2026, and conclude no later than July 15, 2026 [^] [^] [^] [^] .
- Trigger: Prediction markets currently show high sentiment (around 77-83%) that full marijuana rescheduling to Schedule III will occur before January 20, 2029 [^] [^] [^] .
12. Related News
Last updated: June 14, 2026, 22:33 UTC
Marijuana Rescheduling Market Pushes Out Timeline After DOJ Action
Probabilities for a near-term, comprehensive federal rescheduling of marijuana fell sharply on Thursday, April 23, 2026, after the Department of Justice (DOJ) announced a final order that reclassified...
Last updated: June 14, 2026, 22:33 UTC
Marijuana Rescheduling Timeline Compresses Sharply on DOJ News
Prediction markets tracking the federal rescheduling of marijuana saw a sharp, positive repricing on Wednesday, April 22, 2026, as all contracts moved toward a significantly accelerated timeline. The ...
13. Historical Resolutions
No historical resolution data available for this series.
